Base case analysis
| Strategy | Cost ($ (€)) | Incremental cost ($ (€)) | Effectiveness (dQALY) | Incremental effectiveness (dQALY) | Average cost effectiveness ($/dQALY (€/dQALY)) | ICER ($/dQALY (€/dQALY)) | Cancers(/1000 patients) |
|---|---|---|---|---|---|---|---|
| Cost, total cost of the strategy over the lifetime of the patient. | |||||||
| Incremental cost, increased cost the strategy represents over the next least costly strategy over the lifetime of the patient. | |||||||
| Effectiveness, total life expectancy remaining for the patient if treated with that strategy, measured in discounted quality adjusted life years (dQALY). | |||||||
| Incremental effectiveness, increased effectiveness the strategy represents over the next least effective strategy. | |||||||
| Incremental cost effectiveness ratio (ICER), incremental cost divided by the incremental benefit. Represents the additional cost associated with “buying” an additional quality adjusted life year when moving from one less effective strategy to a more effective one. | |||||||
| Cancers per 1000 patients, number of cancers suffered by 1000 theoretical patients if that strategy was pursued. | |||||||
| No preventative strategy | 748 (613) | — | 13.90 | — | 54 (44) | — | 185.4 |
| Oesophagectomy | 34 857 (28 583) | 34 109 (27 969) | 14.89 | 0.99 | 2341 (1920) | Dominated by surveillance | 2.0 |
| Endoscopic surveillance | 34 724 (28 474) | −133 (−109) | 14.96 | 1.06 | 2322 (1904) | 32 053 (26 283) (extended dominance) | 65.2 |
| Endoscopic ablation | 41 998 (34 438) | 7274 (5965) | 15.51 | 0.55 | 2708 (2220) | 25 621 (21 009) | 31.6 |